PGNX Key Statistics, Chart & Performance
The current stock price of PGNX is 4.1 null. In the past month the price increased by 4.59%. In the past year, price decreased by -21.15%.
PGNX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to PGNX. When comparing the yearly performance of all stocks, PGNX is one of the better performing stocks in the market, outperforming 85.06% of all stocks.
PGNX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PGNX. PGNX may be in some trouble as it scores bad on both profitability and health.
PGNX Financial Highlights
Over the last trailing twelve months PGNX reported a non-GAAP Earnings per Share(EPS) of -0.77. The EPS decreased by -13.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -180.28% | ||
| ROA | -67.74% | ||
| ROE | N/A | ||
| Debt/Equity | 0.99 |
PGNX Forecast & Estimates
PGNX Ownership
About PGNX
Company Profile
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.
Company Info
Progenics Pharmaceuticals
ONE WORLD TRADE CENTER 47TH FLOOR
NEW YORK NY 10007
CEO: David W. Mims
Phone: 646-975-2500
Progenics Pharmaceuticals / PGNX FAQ
Can you describe the business of Progenics Pharmaceuticals?
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.
Can you provide the latest stock price for Progenics Pharmaceuticals?
The current stock price of PGNX is 4.1 null. The price decreased by -9.39% in the last trading session.
What is the dividend status of Progenics Pharmaceuticals?
PGNX does not pay a dividend.
How is the ChartMill rating for Progenics Pharmaceuticals?
PGNX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy PGNX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PGNX.
What is the market capitalization of PGNX stock?
Progenics Pharmaceuticals (PGNX) has a market capitalization of 355.05M null. This makes PGNX a Small Cap stock.